Although bullous disorders are not common as an adverse effect among ICI treated cancer patients [277], bullous pemphigoid, the most common blistering disorder, occurs in about 1% of patients treated with PD-1 or PD-L1 inhibitors [34,209,278]. This evidence concerns the gene CD274 and autoimmune bullous skin disease.